HGEN - Humanigen, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.7600
+0.0300 (+4.11%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close0.7300
Open0.7600
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.7600 - 0.8299
52 Week Range0.1300 - 0.8300
Volume7,087
Avg. Volume5,122
Market Cap83.503M
Beta (3Y Monthly)9.18
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)

    Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies to improve the safety and efficacy of chimeric antigen receptor T cell (CAR-T) therapy, announced that final results from the xenograft study of lenzilumab, a first-in-class anti-GM-CSF monoclonal antibody, were presented in the oral plenary session at the 2018 Annual Meeting of the American Society of Hematology, on Monday, December 3rd, 2018 by Rosalie Sterner from Mayo Clinic. The principal investigator for the study was Saad Kenderian, M.B., Ch.B., Mayo Clinic hematologist.   The abstract entitled “GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions” was published as a first edition paper by ‘blood’® in the November 21, 2018 edition and is available online at http://www.bloodjournal.org/content/early/2018/11/21/blood-2018-10-881722.  The full abstract with corresponding figures is available for review at: https://ash.confex.com/ash/2018/webprogram/Paper111766.html.

  • GlobeNewswirelast month

    Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)

    Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release.

  • Lupagen & Humanigen to explore point-of-care CAR-T therapy
    PR Newswire7 months ago

    Lupagen & Humanigen to explore point-of-care CAR-T therapy

    DALLAS , May 22, 2018 /PRNewswire/ -- Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy ...